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outcome of the HTA recorded and the impact of the biomarker test on the submission 
outcome was graded as high, medium or low according to its inﬂ uence on the ﬁ nal 
decision. These ﬁ ndings were summarised, and 6 drugs were selected as case studies in 
order to identify key lessons relating to the risks, consequences, and ethical consider-
ations of Diagnostic/Treatment partnering. RESULTS: The review identiﬁ ed ﬁ ve bio-
markers in the ﬁ ve treatment areas of: HIV, Gastrointestinal stromal tumour (GIST), 
Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), and Breast cancer. 
Markers Her2 and K-RAS had a high impact in all included submissions, with 100% 
and 63% of these submissions resulting in a positive recommendation. In contrast, 
marker EGFR had a lower impact (not mentioned in 4 out of 10 submissions), with 
60% of these submissions being approved, and 40% rejected. The agencies most likely 
to reject a surrogate-outcome submission were PBAC (Australia) and SMC (Scotland) 
with rejection rates of 57% and 66% respectively, whereas CADTH accepted 100% of 
included submissions. CONCLUSIONS: Findings indicate ﬁ rstly that substantially dif-
ferent evidence requirements exist between HTA bodies in the markets considered (e.g. 
differing accuracy acceptability thresholds, prospective/retrospective analysis and the 
importance of cost-effectiveness), and secondly there are several ethical considerations 
to the selection or deselection of patients for treatment.
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OBJECTIVES: HTAinSite is an on-line, subscription-based database of all NICE 
Technology Appraisals (TAs). It includes information relating to submitted evidence, 
appraisal process and ﬁ nal decision and enables assessment of associated trends. 
METHODS: An academic steering group designed and agreed the data extraction 
protocol. a team of reviewers conducted the initial data extraction, which was vali-
dated by a second reviewer. Historical extraction is complete, with on-going TAs 
extracted on a monthly basis. RESULTS: A total of 181 TAs have been extracted to 
date, 5 of which were terminated, resulting in 176 complete TAs relating to 326 tech-
nologies. Of these, 53% were awarded a restricted decision, 32% were fully recom-
mended and 16% rejected. Of the three most commonly appraised disease areas (cancer, 
cardiovascular (CVS), central nervous system (CNS); CVS technologies were least com-
monly rejected by NICE (3% vs. 21% for cancer and 17% for CNS). Of the four most 
commonly used assessment groups (Shefﬁ eld, York, Southampton and Birmingham); 
technologies assessed by Shefﬁ eld were most commonly rejected (28%) and those by 
York were least commonly rejected (4%). Technologies supported by a patient submis-
sion were less commonly rejected than those without (15% vs. 29%). a total of 35 TAs 
(20%) resulted in an appeal, no appeals were upheld entirely, all appeals were upheld 
partially. HTAinSite also allows detailed analysis of individual TAs and cross-compar-
ison between TAs as well as identifying trends between submitted evidence (acquisition 
costs, budget impact, cost-effectiveness and clinical effectiveness) and ﬁ nal outcome. 
These additional analyses will be further explored in the poster and preliminary results 
will also be updated. CONCLUSIONS: HTAinSite is a useful tool for anyone interested 
in understanding the relationship between submitted evidence and ultimate NICE 
decision. The HTAinSite format may be useful for other HTA bodies, depending on 
the public availability of relevant information.
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OBJECTIVES: Mathematical models are required by decision makers to provide 
insight into pharmcoeconomic beneﬁ ts associated with a product. It is therefore 
essential that manufacturers understand economic evidence requirements when sub-
mitting an application to a Health Technology Assessment (HTA) agency. METHODS: 
A literature search of economic recommendations from the following HTA agencies 
was conducted: CADTH (Canada), HAS (France), IQWiG (Germany), NICE 
(England), PBAC (Australia), PHARMAC (New Zealand) and SMC (Scotland). 
RESULTS: Cost-effectiveness analysis is considered the most relevant analytical tech-
nique across the English-speaking agencies with a preference for QALY-based analysis, 
in contrast to IQWiG which does not consider QALYs and utilities as central to their 
methods. Unlike other HTA agencies assessed, the French agency HAS does not cur-
rently require cost-effectiveness modelling in its decision-making process. EQ-5D is 
the most commonly used utility instrument, NICE being the most prescriptive agency 
in this regard. However, utilities mapped from disease-speciﬁ c quality of life measures 
may be accepted and agencies such as PBAC and IQWiG express no formal preference 
between instruments. The third-party payer is the most commonly required perspective 
adopted across the English-speaking agencies while IQWiG and PBAC recommend a 
societal perspective in addition to the payer’s perspective. This trend towards a 
broader, societal perspective may, however, be limited by uncertainties around mea-
surement of wider costs. Sensitivity analyses are required by all agencies to explore 
uncertainty in the model. NICE and CADTH both favor a probabilistic approach 
while PBAC prefers univariate and multivariate analyses. Other agencies expect the 
manufacturer to justify their approach and choice. CONCLUSIONS: The recommen-
dations of IQWiG and PBAC differ from the other selected agencies. Uniquely, in 
France the pharmaeconomic case is considered separately from the HTA process by 
the French Health Economists Association. These differences between agencies should 
be considered when planning evidence generation activities to support economic model 
development.
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OBJECTIVES: Health Technology Assessment (HTA) agencies require various types 
and qualities of evidence for clinical effectiveness evaluations due to differences in 
health care systems and policies. It is essential for manufacturers to understand these 
requirements when submitting an application to each individual HTA agency. 
METHODS: A literature search of clinical recommendations from the following HTA 
agencies was conducted for comparison: CADTH (Canada), HAS (France), IQWiG 
(Germany), NICE (England), PBAC (Australia), PHARMAC (New Zealand) and SMC 
(Scotland). RESULTS: The choice of the optimal comparator is crucial to the outcome 
of the HTA. Almost all agencies prefer comparison versus the most frequently used 
interventions except for PBAC which requires comparison to the interventions most 
likely to be displaced. All HTA agencies are cautious in their interpretation of sur-
rogate outcomes (SO) and require manufacturers to provide evidence linking the SO 
to ﬁ nal patient-relevant outcomes. PBAC has notably developed a framework for 
assessing SOs and the impact of these on uncertainty in HTA submissions. Most 
agencies except for NICE clearly state their position on the deﬁ nition and the use of 
SOs. All agencies recognize the value of observational studies in reﬂ ecting real-world 
situations and providing long-term data although RCTs provide the key evidence on 
comparative effectiveness. Systematic reviews (SR) of clinical evidence are essential to 
present comparative effectiveness relative to all comparators. Contrary to most agen-
cies, HAS prefers SRs but does not require them and bases its assessments mainly on 
pivotal clinical trials provided by the manufacturer. NICE and IQWiG also differ from 
the other agencies as they perform in-house SR in addition to the manufacturer’s. 
CONCLUSIONS: The differences between agency requirements are subtle and mean 
that manufacturers need to put together a solid clinical evidence package needing very 
little adaptation to meet the seven country requirements.
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OBJECTIVES: The EUnetHTA Joint Action (2010–2012) is a joint initiative by EU 
Member States and the European Commission to advance European collaboration on 
health technology assessment (HTA). Part of the EUnetHTA Joint Action aims at 
reviewing methods used for the relative effectiveness assessment (REA) of pharmaceu-
ticals and to develop, apply and ﬁ eld-test tools and methods. As a ﬁ rst step towards 
this goal, objectives, processes and methodologies used for REA by HTA organizations 
across Europe and other countries are summarised. This overview is crucial for the 
development of shared or common methodologies to be used in future REA across 
Europe. METHODS: Data were captured with a standardised data abstraction form. 
Data were initially abstracted from different types of literature (peer reviewed, grey 
literature, EU and national reports etc.). Where there were gaps in the data, telephone 
interviews were arranged with a relevant person at the respective HTA or reimburse-
ment agency. RESULTS: Most European countries carry out some form of REA, 
however the deﬁ nitions of the assessments in general are not consistent with the deﬁ ni-
tion by the Pharmaceutical Forum. In addition the scope (inclusions of beneﬁ t-risk 
analysis and/or a cost-effectiveness analysis), the process (timing, involvement of 
stakeholders and separation of assessment and appraisal phase) and the purpose 
(inform clinical decision-making, reimbursement and/or for pricing decision-making) 
of the assessments vary as well as the methods (such as inclusion of surrogate end-
points, composite endpoints and quality of life data and extrapolation of efﬁ cacy 
data). Most agencies publish a guideline for the methodology used for REA however 
few publish them in English. CONCLUSIONS: A considerable number of European 
countries carry out REAs. However, the purpose and the methodology used vary 
across Europe. The reasons behind these differences need to be considered in the 
development of a common European methodology for REA. 
HEALTH CARE USE & POLICY STUDIES – Population Health
PHP110
PHYSICIANS’ VIEWS OF THE RELATIVE IMPORTANCE OF SELECTED 
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OBJECTIVES: To identify the pharmaceutical and medical innovations that contributed 
mostly to the improvement of Greek population health status during the last three 
decades, according to physicians’ views. METHODS: Building on the methodology by 
Fuchs and Sox, a questionnaire based survey was conducted on a representative sample 
of 500 Greek internists and general practitioners aged ≥50 years old. The study question-
naire was formulated by a panel of experts, with the use of the Delphi method and 
included one list of 22 pharmaceutical and a second list of 20 medical innovations. 
Physicians were asked to identify the seven more important and seven least important 
